Spectral Medical (STU:SD4) Cyclically Adjusted Revenue per Share: €0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SD4 Spectral Medical Inc STU:SD4
14 GF Score
Price €0.83
GF Value €0.56
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Spectral Medical Cyclically Adjusted Revenue per Share?

Spectral Medical STU:SD4 +1.23% 14 Cyclically Adjusted Revenue per Share is €0.01 as of Mar. 2026. GuruFocus rates STU:SD4 with a GF Score™ of 14/100 and a GF Value™ of €0.56 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Spectral Medical's adjusted revenue per share for the three months ended in Mar. 2026 was €0.002. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.01 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -20.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -14.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Spectral Medical was 13.00% per year. The lowest was -34.10% per year. And the median was -20.60% per year.

As of today (2026-07-15), Spectral Medical's current stock price is €0.825. Spectral Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.01. Spectral Medical's Cyclically Adjusted PS Ratio of today is 82.50.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Spectral Medical was 170.00. The lowest was 3.17. And the median was 18.25.


Spectral Medical  (STU:SD4) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Spectral Medical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.825/0.01
=82.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Spectral Medical was 170.00. The lowest was 3.17. And the median was 18.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Spectral Medical Cyclically Adjusted Revenue per Share Related Terms


Spectral Medical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Spectral Medical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spectral Medical Cyclically Adjusted Revenue per Share Chart

Spectral Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Spectral Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

STU:SD4 vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Spectral Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectral Medical Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Spectral Medical's Cyclically Adjusted PS Ratio falls into.


STU:SD4
14GF Score
Spectral Medical Inc STU:SD4
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spectral Medical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spectral Medical's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.002/132.2623*132.2623
=0.002

Current CPI (Mar. 2026) = 132.2623.

Spectral Medical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.003 102.002 0.004
201609 0.003 101.765 0.004
201612 0.003 101.449 0.004
201703 0.003 102.634 0.004
201706 0.003 103.029 0.004
201709 0.003 103.345 0.004
201712 0.003 103.345 0.004
201803 0.004 105.004 0.005
201806 0.001 105.557 0.001
201809 0.002 105.636 0.003
201812 0.005 105.399 0.006
201903 0.002 106.979 0.002
201906 0.003 107.690 0.004
201909 0.002 107.611 0.002
201912 0.002 107.769 0.002
202003 0.002 107.927 0.002
202006 0.001 108.401 0.001
202009 0.001 108.164 0.001
202012 0.001 108.559 0.001
202103 0.002 110.298 0.002
202106 0.002 111.720 0.002
202109 0.001 112.905 0.001
202112 0.001 113.774 0.001
202203 0.001 117.646 0.001
202206 0.001 120.806 0.001
202209 0.001 120.648 0.001
202212 0.001 120.964 0.001
202303 0.001 122.702 0.001
202306 0.001 124.203 0.001
202309 0.001 125.230 0.001
202312 0.001 125.072 0.001
202403 0.002 126.258 0.002
202406 0.001 127.522 0.001
202409 0.001 127.285 0.001
202412 0.002 127.364 0.002
202503 0.001 129.181 0.001
202506 0.002 129.892 0.002
202509 0.001 130.287 0.001
202512 0.001 130.366 0.001
202603 0.002 132.262 0.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.01 mean?
Spectral Medical (STU:SD4) has a Cyclically Adjusted Revenue per Share of €0.01 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Spectral Medical and its competitors.
Is Spectral Medical's Cyclically Adjusted Revenue per Share too high?
Spectral Medical's current Cyclically Adjusted Revenue per Share is €0.01. Overall, Spectral Medical has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Spectral Medical's Cyclically Adjusted Revenue per Share of €0.01 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Spectral Medical and its competitors. Spectral Medical's current Cyclically Adjusted Revenue per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (STU:SD4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.56, compared to a current price of €0.83 — trading 47.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.01. Spectral Medical's overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Spectral Medical (STU:SD4), the current Cyclically Adjusted Revenue per Share is €0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spectral Medical (STU:SD4) Overvalued in 2026?

Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued. The current stock price of €0.83 is trading 47.3% above its estimated GF Value™ of €0.56. GuruFocus considers Spectral Medical to be Significantly Overvalued.

Key valuation signals for STU:SD4:

  • Cyclically Adjusted Revenue per Share: €0.01
  • GF Value™: €0.56 vs. price of €0.83 (47.3% above fair value)
  • GF Score™: 14/100 with 9 warning signs

No single metric tells the full story. See the STU:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spectral Medical Business Description

Other Exchanges EDTXF:USAEDT:Canada
Address 135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
14GF Score

Get the complete analysis for STU:SD4

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.83
Price
€0.56
GF Value